Articles On Adalta (ASX:1AD)

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

As with almost every other drug developer on the planet, Vectus Biostsyems (ASX:VBS) co-founder Maurie Stang believes his fibrotic diseases outfit is of interest to potential, deep-pocketed partners. The difference is that given his life sc...

Twiggy’s Tattarang has seeded a new fund called Tenmile with $250m Tenmile will focus mainly on Aussie biotechs Here are the ASX stocks that will benefit Andrew “Twiggy” Forrest’s business philosophy has always been: “You bite off more th...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

AdAlta (1AD) receives a European patent from the European Patent Office for its lead product AD-124 The patent is titled “CXCR4 binding molecules” and has an expiry date of January 8, 2036 It protects the i-body sequence used in AD-214, s...

The ASX 200 is set to open 4% lower today Wall Street crashes following higher than expected inflation report on Friday Bitcoin plunges 13% The ASX is poised to crash by more than 4% at the open this morning after another plunge in Wall S...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Highlights Today, the S&P/ASX 200 Financial sector (ASX:XFJ) traded approximately 0.843% lower at 6730.100 points at 12:06 PM AEDT. The benchmark index ASX200 was trading 0.528% lower at 7450.600 points at 11:23 AM AEST. Three ASX...

Highlights AdAlta’s lead i-body candidate AD-214 has bagged its first Indian patent. The patent entitled “CXCR4 binding molecules” is valid till 08 January 2036 AdAlta aims to partner with other biopharmaceutical companies to maximise...

AdAlta gets first patent in India RhinoMed to start selling Covid swaps and RAT kits in Canada AdAlta (ASX:1AD) has received an Indian patent for its lead program, AD-214. The new patent protects the i-body sequence used in AD-214, as wel...

The US Fed plans to reduce its bond back by US$95bn a month Nasdaq plunged another 2% ASX to open lower this morning Wall Street skids on US Fed’s plan Aussie shares are poised to follow Wall Street into the red today, with the ASX 200 Ap...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

The ASX 200 Health Index (XHJ) is up by 0.30% at the time of writing, compared to the broader index which is up by 0.60%. Clinical stage cannabis biotech, Emyria (ASX: EMD), announced that participant recruitment, screening and consenting h...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

AdAlta (1AD) has been granted a patent for its lead product AD-214 by the China National Intellectual Property Administration The new patent protects the i-body sequence used in AD-214 and pharmaceutical compositions and diagnostic applica...

The ASX 200 Health Index (XHJ) is trading lower by 0.27% at the time of writing, compared to the broader index which is falling by 0.56%. Pain relief specialist Medical Development International (ASX:MVP) announced that the US FDA has uncon...

Wall Street tumbles, ASX to fall as oil prices spike Aussie shares are set to follow Wall Street into the red today, as oil prices surged by as much as 10% overnight. As fighting in the Ukraine intensified, the US and other major economies...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

ShareCafeWebinar Recap – TNR, LBT, 1AD & LIT Catch up on the full webinar with presentations from Torian Resources (ASX: TNR), LBT Innovations (ASX: LBT),  Adalta (ASX: 1AD) & Lithium Australia (ASX: LIT) Webinar Recap – TNR...

ShareCafeAdAlta (ASX: 1AD) – Webinar Presentation Tim Oldham – CEO and Managing Director – AdAlta is a clinical-stage biotechnology company that uses its i-body platform to discover and develop next-generation protein therapeutics addressi...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

The ASX started the week lower as a result of a drop in the energy and financial sectors. Energy shares fell by over 3%, as surging cases of the Omicron variant raised fears that new restrictions may hit fuel demand. Financials meanwhile we...

Clinical-stage biotech company AdAlta (1AD) is looking to raise up to $5.95 million through a placement and non-renounceable entitlement offer The company received commitments from investors for the placement, which is raising $3.75 millio...

The so-called ‘Santa Claus Rally’ appears to be happening again this year with the ASX notching another positive day. The ASX 200 closed at 7,379 points which was 0.35% higher than Friday, following on from a 1.6% gain last week and positiv...

For the first time in over a month, the ASX finished a week higher than where it began — even with the bourse declining on an intraday basis. The ASX 200 closed at 7,353 points which was 0.42% lower than yesterday, but up 1.6% from last Fri...

Clinical-stage drug developer AdAlta (1AD) has entered a trading halt while it plans and completes a capital raise 1AD recently announced positive outcomes from early testing of its AD-214 drug candidate which is being developed for future...

The ASX 200 Health Index (XHJ) is down by 0.20% at the time of writing, compared to the broader index which is down by 0.35%. Brain-focused company, Argenica Therapeutics (ASX:AGN), has just been awarded a US patent relating to the use of i...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Wall Street retreats overnight All three US stock market indexes retreated overnight, with the Dow Jones falling by 0.58% , the S&P 500 by 0.26%, and tech heavy Nasdaq by 0.33%. US retailer Target’s Q3 revenues smashed estimates, but co...

AdAlta (ASX:1AD) has announced an amendment to its funding agreement with MTPConnect under the Australian Government’s MRFF’s Biomedical Translation Bridge program with the support of UniQuest.

Australia’s bourse had its biggest decline since February 26 falling by over 2%. The ASX 200 fell 2.1% to close at 7,248 and is down 5% since August 13. The ASX Emerging Companies Index fared worse, losing over 4% in its worst day since Apr...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

The CAR T-cell therapy (Chimeric Antigen Receptor) has been billed as a radical new way to cure cancer. But since the US FDA approved the first cell-gene therapy to treat leukemia in 2018, the technology has not really caught on in the main...

Highlights: AdAlta and Carina Biotech enter a collaboration agreement to develop i-body enabled CAR-T cancer immunotherapies against up to five solid tumour antigen targets Combining Carina’s advanced CAR-T platform technologies with AdAl...

It was another positive close for the Australian bourse today with energy the standout sector. The ASX 200 closed 0.17% higher at 7,503 points while the ASX Emerging Companies Index gained 1.1% to close at 2,262 points. Leading the charge w...

Leading the health stocks today is Nanosonics (ASX:NAN)  up 19.69% after flagging FY21 revenues of $103.1 million, with strong momentum in H2 where revenues came in at $60 million – up 39% from H1. The company installed 3,030 units of its a...

AdAlta Limited (ASX:1AD) and Carina Biotech have announced a collaboration agreement to develop next-generation i-body enabled CAR-T cells.

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Whisky manufacturer Lark Distilling Co (ASX:LRK) kept things warm during winter, leading a group of 25 stocks that posted a 14-day RSI above 70 last week. Each week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Relat...

Australian shares have extended gains for the second day in a row, rising by 0.91% despite more COVID cases across states. All 11 sectors were in the green, except for Healthcare. Mining and Energy led the gains, rising by 2% each, buoyed b...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

The Aussie share market has fallen for two consecutive days, down by 0.46% today. Seven sectors were down, while four rose. Utilities and Mining were the worst peforming sectors, while Healtcare and IT were the best. In big cap news today,...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...